Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Open accessThe DOI matches its Crossref record; 427 of the 427 references it cites were found in a registry or an index.
Abstract
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant, primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic heterogeneity, and protection by the blood brain barrier (BBB) have posed great treatment challenges. The standard treatment for GBMs is surgical resection followed by chemoradiotherapy. The robust DNA repair and self-renewing capabilities of glioblastoma cells and glioma initiating cells (GICs), respectively, promote resistance against all current treatment modalities. Thus, durable GBM management will require the invention of innovative treatment strategies. In this review, we will describe biological and molecular targets for GBM therapy, the current status of pharmacologic therapy, prominent mechanisms of resistance, and new treatment approaches. To date, medical imaging is primarily used to determine the location, size and macroscopic morphology of GBM before, during, and after therapy. In the future, molecular and cellular imaging approaches will more dynamically monitor the expression of molecular targets and/or immune responses in the tumor, thereby enabling more immediate adaptation of tumor-tailored, targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–427 of 427
Deng, Z., Sheng, Z., & Yan, F. (2019) · Journal of Oncology · doi:10.1155/2019/2345203 · Cited by 30
Epigenetic Pathways and Glioblastoma Treatment: Insights From Signaling Cascades
Allen, B. K., Stathias, V., Maloof, M. E., Vidović, D., Winterbottom, E. F., Capobianco, A. J., Clarke, J., Schürer, S. C., Robbins, D. J., & Ayad, N. G. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24990 · Cited by 29
Yaacoub, C., Mhanna, G., & Rihana, S. A. (2017) · Brain Sciences · doi:10.3390/brainsci7010012 · Cited by 29
Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
Mesti, T., Moltara, M. E., Boc, M., Reberšek, M., & Ocvirk, J. (2014) · Radiology and Oncology · doi:10.2478/raon-2014-0021 · Cited by 28
The Role of Liquid Biopsies in Pediatric Brain Tumors
Tang, K., Gardner, S. L., & Snuderl, M. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaa068 · Cited by 28
Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma
Rhun, É. L., Devos, P., Houillier, C., Cartalat‐Carel, S., Chinot, O. L., Stefano, A. L. D., Lepage, C., Reyns, N., Dubois, F., & Weller, M. (2019) · Neurology · doi:10.1212/wnl.0000000000008440 · Cited by 27
Baran, K., Yang, M., Dillon, C. P., Samson, L. D., & Green, D. R. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.116 · Cited by 23
Cancer Progenitor Cells: The Result of an Epigenetic Event?
LAPINSKA, K., Faria, G. N. F., McGonagle, S., Macumber, K. M., Heerboth, S. A., & Sarkar, S. (2018) · Anticancer Research · doi:10.21873/anticanres.12184 · Cited by 23
Theranostic nanoparticles enhance the response of glioblastomas to radiation
Wu, W. E., Klockow, J., Mohanty, S., Ku, K. S., Aghighi, M., Melemenidis, S., Chen, Z., Li, K., Morais, G. R., Zhao, N., et al. (2019) · Nanotheranostics · doi:10.7150/ntno.35342 · Cited by 23
Self-citationTargeting the Synthetic Vulnerability of PTEN -Deficient Glioblastoma Cells with MCL1 Inhibitors
Chen, C., Zhu, S., Zhang, X., Zhou, T., Gu, J., Xu, Y., Wan, Q., Qi, X., Chai, Y., Liu, X., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0099 · Cited by 23
Erlotinib in Glioblastoma - Lost in Translation?
Karpel‐Massler, G., Westhoff, M., Kast, R. E., Wirtz, C. R., & Halatsch, M. (2011) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152011797378788 · Cited by 20
Liu, P., Liu, G., Wang, G., Zhou, W., Sun, Y., Chen, W., Zeng, Q., Hong, J., Xie, Q., Ou, L., et al. (2020) · BioMed Research International · doi:10.1155/2020/4258989 · Cited by 19
Cancer stem cells and nanotechnological approaches for eradication
Basati, G., Khaksarian, M., Abbaszadeh, S., Lashgarian, H. E., & Marzban, A. (2019) · Stem Cell Investigation · doi:10.21037/sci.2019.10.07 · Cited by 18
Epigenetics of Solid Cancer Stem Cells
Mishra, A., & Verma, M. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-612-8_2 · Cited by 17
Choi, P. J., Cooper, E., Schweder, P. M., Mee, E. T., Turner, C. P., Faull, R. L. M., Denny, W. A., Dragunow, M., Park, T., & Jose, J. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127252 · Cited by 17
Pan, Z., Zhang, S., Wang, X., Jiao, Y., & Qiu, J. (2020) · Behavioural Neurology · doi:10.1155/2020/1712604 · Cited by 17
Re-Examining the Need for Tissue Diagnosis in Pediatric Diffuse Intrinsic Pontine Gliomas: A Review
Infinger, L. K., & Stevenson, C. B. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160425114024 · Cited by 16
Meng, W., Jiang, Y., & Ma, J. (2017) · Cancer Management and Research · doi:10.2147/cmar.s140447 · Cited by 16
Mehner, M., Kubelt, C., Adamski, V., Schmitt, C. R., Synowitz, M., & Held‐Feindt, J. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03107-7 · Cited by 14
Yang, J., ZHU, X.-B., He, L., Gu, Z., Jin, M., & Ji, W. (2014) · Oncology Letters · doi:10.3892/ol.2014.2662 · Cited by 13
Ozel, O., Kurt, M., Özdemir, O., Bayram, J., Akdenız, H., & Koca, D. (2016) · Journal of Oncological Sciences · doi:10.1016/j.jons.2016.07.009 · Cited by 13
Immunohistochemical Assessment of MGMT Expression and p53 Mutation in Glioblastoma Multiforme
Lotfi, M., Afsharnezhad, S., Raziee, H., Ghaffarzadegan, K., Sharif, S., Shamsara, J., Lary, S., & Behravan, J. (2011) · Tumori Journal · doi:10.1177/030089161109700118 · Cited by 12
Tailored therapy for recurrent glioblastoma: report of a personalized molecular approach
D’Alessandris, Q. G., Martini, M., Cenci, T., Bonaventura, R. D., Lauretti, L., Stumpo, V., Olivi, A., Larocca, L. M., Pallini, R., & Montano, N. (2022) · Journal of Neurosurgical Sciences · doi:10.23736/s0390-5616.20.04943-7 · Cited by 12
Zenkoh, J., Gerelchuluun, A., Wang, Y., Miwa, Y., Ohno, T., & Tsuboi, K. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.01.32 · Cited by 12
Drug Delivery Systems Using Surface Markers for Targeting Cancer Stem Cells
Oswald, J. T., Patel, H., Khan, D. A., Jeorje, N. N., Golzar, H., Oswald, E. L., & Tang, X. S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200406084900 · Cited by 10
Lower MGMT expression predicts better prognosis in proneural-like glioblastoma.
He, Z.-C., Ping, Y., Xu, S., Lin, Y., Yu, S., Kung, H., & Bian, X. (2015) · PubMed · Cited by 8
Cerebrospinal fluid–suppressed T2‐weighted MR imaging at 7 T for human brain
Pan, J. W., Moon, C., & Hetherington, H. P. (2018) · Magnetic Resonance in Medicine · doi:10.1002/mrm.27598 · Cited by 7
Cited by
Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier
Zha, S., Liu, H., Li, H., Li, H., Wong, K.-L., & All, A. H. (2024) · ACS Nano · doi:10.1021/acsnano.3c10674 · Cited by 378
Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
Yalamarty, S. S. K., Filipczak, N., Li, X., Subhan, M. A., Parveen, F., Ataide, J. A., Rajmalani, B. A., & Torchilin, V. P. (2023) · Cancers · doi:10.3390/cancers15072116 · Cited by 293
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Glioblastoma modeling with 3D organoids: progress and challenges
Wang, X., Sun, Y., Zhang, D. Y., Ming, G.-L., & Song, H. (2023) · Oxford Open Neuroscience · doi:10.1093/oons/kvad008 · Cited by 46
“Treatment resistance and recurrence of GBM are mainly driven by several characteristics including, but not limited to, diffuse infiltration of brain parenchyma, rapid proliferation, high intertumoral and intratumoral heterogeneity and an immune-cold tumor microenvironment [4].”
BackgroundSarli, S. L., Fakih, H. H., Kelly, K., Devi, G., Rembetsy-Brown, J. M., McEachern, H. R., Ferguson, C. M., Echeverria, D., Lee, J., Sousa, J., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae260 · Cited by 18
Metadata
- Authors
- Wu, W., Klockow, J. L., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 171
- Pages
- 105780
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W3185482622
- Cited by
- 805
- References
- 427
- FWCI
- 43.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.